公开(公告)号：US20220080034A1

公开(公告)日：2022-03-17

申请号：US17531897

申请日：2021-11-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yair REISNER ,  Noga OR-GEVA ,  Eran OPHIR ,  Yaki EIDELSTEIN ,  Rotem GIDRON BUDOVSKY

IPC: A61K39/00 ,  A61K35/17 ,  C12N5/078 ,  C12N5/0783 ,  A61P31/00 ,  A61P35/04 ,  A61K39/395 ,  C07K16/28

Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

公开(公告)号：US20220031776A1

公开(公告)日：2022-02-03

申请号：US16644641

申请日：2018-09-07

Applicant: Keio University ,  BiomX Ltd. ,  Yeda Research and Development Co. Ltd. at the Weizmann Institute of Science

Inventor： Kenya Honda ,  Koji Atarashi ,  Seiko Narushima ,  Eran Elinav ,  Rotem Sorek ,  Efrat Khabra ,  Hava Ben David ,  Eyal Weinstock ,  Sarah Pollock ,  Yulia Matiuhin ,  Naomi Zak

IPC: A61K35/76 ,  C12N7/00

Abstract: Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.

公开(公告)号：US20210369761A1

公开(公告)日：2021-12-02

申请号：US17391125

申请日：2021-08-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Eran HORNSTEIN ,  Irit REICHENSTEIN ,  Alon CHEN

IPC: A61K31/7105 ,  C12N15/113 ,  A61K45/06 ,  A61P25/00

Abstract: A method of treating a subject having MND is provided. The method comprising administering to the subject a therapeutically effective amount of an agent selected from the group consisting of miR-218, miR-218*, precursor thereof and a polynucleotide sequence encoding miR-218 or miR-218* or precursor thereof, thereby treating the MND in the subject. A method of treating a subject having MND, the method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating an activity or expression of a gene product selected from the group consisting of KCND2, KCNH1, GABRB2, SLC6A1, SLC6A11, KCNA1, CACNB4, GRIA2, GRIK2, GABRG1 and GRIK3, is also provided.

公开(公告)号：US11174561B2

公开(公告)日：2021-11-16

申请号：US16771243

申请日：2018-12-10

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Ronny Neumann ,  Alexander Khenkin ,  Miriam Somekh

IPC: C25B3/23 ,  C25B3/07 ,  B01J23/78 ,  C25B1/02

Abstract: The invention relates to electrocatalytic processes for the formation of formate esters using at least one catalyst or pre-catalyst; wherein the formate ester can be further hydrolyzed.

公开(公告)号：US11167005B2

公开(公告)日：2021-11-09

申请号：US16474831

申请日：2018-01-04

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Edna Mozes

IPC: A61K38/04 ,  A61K38/10 ,  A61P11/00 ,  A61P15/00 ,  A61P17/00 ,  A61P17/16 ,  A61P19/02 ,  A61P1/02 ,  A61P27/02 ,  A61P37/02 ,  A61P43/00 ,  C07K7/08

Abstract: Compositions and methods for the treatment of Sjogren's syndrome (SS) and SS-related symptoms in human subjects are described. The compositions comprise synthetic peptides based on the sequence of CDR1 of an anti-DNA monoclonal antibody.

公开(公告)号：US20210332024A1

公开(公告)日：2021-10-28

申请号：US17370216

申请日：2021-07-08

Applicant: Yeda Research and Development Co. Ltd. ,  Dana-Farber Cancer Institute, Inc. ,  Beth Israel Deaconess Medical Center, Inc.

Inventor： Nir LONDON ,  Daniel ZAIDMAN ,  Christian DUBIELLA ,  Nathanael S. GRAY ,  Benika Joan PINCH ,  Kun Ping LU ,  Alfred Thomas LOOK ,  Shuning HE ,  Xiao Zhen ZHOU ,  Xiaolan LIAN

IPC: C07D333/16

Abstract: Disclosed herein are compounds comprising an electrophilic moiety and rigid moiety for use in modulating an activity of Pin1. The rigid moiety comprises at least one functional group that is capable of forming hydrogen bonds with hydrogen atoms, wherein the electrophilic moiety and the rigid moiety are arranged such that the electrophilic moiety is capable of covalently binding to the Cys113 residue of Pin1, and the rigid moiety is capable of forming hydrogen bonds with the Gln131 and His 157 residues of Pin1. Further disclosed are novel compounds having Formula Id: wherein the dashed line, W, X, Y, Z, Ra-Rc, R1, R2, L1, L2 and n are as defined herein, and libraries comprising such compounds. Further disclosed are methods of identifying a compound capable of modulating an activity of Pin1, by screening a library of compounds.

公开(公告)号：US20210292437A1

公开(公告)日：2021-09-23

申请号：US17267049

申请日：2019-08-14

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Deborah FASS ,  Sarel FLEISHMAN ,  Shira WARSZAWSKI ,  Iris GROSSMAN ,  Lev KHMELNITSKY

IPC: C07K16/40

Abstract: Antibodies for binding QSOX1 are provided. Also provided are use of these antibodies.

公开(公告)号：US20210292338A1

公开(公告)日：2021-09-23

申请号：US17337570

申请日：2021-06-03

Applicant: Yeda Research and Development Co. Ltd. ,  Universitat de Barcelona ,  Institució Catalana de Recerca I Estudis Avançats

Inventor： Rony SEGER ,  Karen FLORES ,  Xavier BARRIL ALONSO ,  Carlos GALDEANO CANTADOR

IPC: C07D498/04 ,  A61K45/06 ,  A61P35/00

Abstract: Described herein are compounds having Formula I or Formula II: wherein each dashed line independently represents a saturated or unsaturated bond; R1 and R′1 are aryl or heteroaryl as defined herein; and R2 and R′2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.

公开(公告)号：US11111481B2

公开(公告)日：2021-09-07

申请号：US15764691

申请日：2016-09-29

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD. ,  YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  SYNVACCINE LTD.

Inventor： Tamir Tuller ,  Eli Goz ,  Shimshi Atar ,  Hadas Zur

IPC: C12N7/00 ,  C12N7/04 ,  A61K35/76 ,  A61K35/12 ,  G16B99/00 ,  A61K39/12 ,  A61K39/00

Abstract: Attenuated viruses and methods of designing them are disclosed. In one embodiment, there is disclosed an attenuated form of a virulent virus comprising an RNA encoding a viral protein or a nucleic acid sequence transcribable to said RNA, wherein the folding energy or structure of the RNA is changed at positions of evolutionarily conserved RNA structures with respect to that of said RNA encoding said viral protein in the virulent virus so as to bring about attenuation of the virus.

公开(公告)号：US11053434B2

公开(公告)日：2021-07-06

申请号：US15758344

申请日：2016-09-08

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Milko E. Van Der Boom ,  Michal Lahav ,  Neta Elool Dov

IPC: G02F1/1516 ,  B05D5/06 ,  B05D1/00 ,  B05D7/00 ,  C09K9/02 ,  C07D213/22 ,  C07F15/02 ,  C09D5/29

Abstract: The invention is directed to methods for making an EC material comprising providing a substrate, applying at least one metal linker to the substrate, applying at least one metal-coordinated organic complex to form a layer, washing the layer, drying the layer, and repeating the applying steps to obtain a multiple layer EC material. The invention is further directed to EC materials made by the methods of this invention.